A new unified approach to process analytical technologies from Recipharm Advanced Bio aims to replace fragmented, off-line testing with integrated real-time analytics—cutting development and release timelines by up to 50% while aligning with FDA-backed continuous manufacturing initiatives and a multibillion-dollar global PAT market opportunity.